1. Introduction {#s0005}
===============

Health insurers in Japan are required to offer annual health checkups to their enrollees aged 40--74 years to prevent and reduce the prevalence of lifestyle diseases such as hypertension, diabetes, and dyslipidemia ([@b0075]). These health checkups are designed to identify individuals at high risk of developing the target diseases, and are composed of medical consultations, physical examinations, blood pressure (BP) measurements, urine tests, and blood tests ([@b0075]). Older adults aged ≥ 75 years (hereinafter referred to as older adults) are also offered a similar annual health checkup to identify at-risk individuals ([@b0085]). In Tokyo, older adults can undergo this health checkup for a cost of less than 500 yen (\<\$5) ([@b0110]). Older adults in Japan accounted for 13% of its population in 2015, and this proportion is expected to rise to 18% by 2025 ([@b0015]). Accordingly, there is an urgent need to design and implement an effective and efficient health checkup system that specifically addresses the major health concerns of this population.

Older adults generally have a higher prevalence of hypertension, diabetes, and dyslipidemia than younger people ([@b0010], [@b0040], [@b0030]), and are more likely to receive pharmacological treatments for these diseases. The pharmacological treatment rates among older Tokyo residents are approximately 60% for hypertension, 15% for diabetes, and 35% for dyslipidemia ([@b0060]). It is possible that health checkups aimed at the early detection of these diseases in older adults---many of whom are already diagnosed and being treated---would not have any demonstrable benefits. It is therefore important to examine if older adults who undergo annual health checkups are already receiving pharmacological treatments for these diseases. However, little remains known about the associations between these pharmacological treatments in older adults and their participation in annual health checkups.

The Japanese government has highlighted the need for disease management support during annual health checkups for older adults ([@b0050]). In many other countries, treatment guidelines for hypertension and diabetes in older adults emphasize balancing treatment with disease burden ([@b0020], [@b0025], [@b0035], [@b0090], [@b0095]). The American College of Physicians advocates that physicians refrain from setting hemoglobin A1c (HbA1c) targets below 7% in most patients with type 2 diabetes, and avoid any HbA1c targets for adults aged ≥ 80 years ([@b0090]). Similarly, Japanese treatment guidelines for older patients with diabetes recommend mild glycemic control that takes into account each patient's age, cognitive function, physical function, comorbidities, risk for severe hypoglycemia, and life expectancy ([@b0025]). Furthermore, various countries' guidelines for the management of hypertension in older adults recommend a BP goal of \<150/90 mmHg ([@b0035], [@b0020], [@b0095]) instead of \<140/90 mmHg, which is used for younger adults. Despite these recommendations, the optimal glycemic and BP treatment targets for older adults remain undetermined ([@b0120]). Monitoring the management of BP, HbA1c, and lipid levels among older adults receiving pharmacological treatments for hypertension, diabetes, and dyslipidemia would be the first step in effectively controlling these diseases. A previous study had evaluated the management of these diseases in adults aged \<75 years who underwent health checkups ([@b0065]). However, few studies have focused on the management of older adults who are already receiving pharmacological treatments for these diseases.

We have previously developed a database that links medical claims data with health checkup data in older adults residing in Tokyo. Here, we present two analyses (designated Analysis I and Analysis II) that utilize this database with the aim of improving the ability of Japan's health checkup system to address and monitor the major health concerns of older adults. In Analysis I, we examined the associations of pharmacological treatments for hypertension, diabetes, and dyslipidemia with health checkup participation in older adults. In Analysis II, we identified the factors associated with disease control for hypertension, diabetes, and dyslipidemia in older adults receiving pharmacological treatments.

2. Methods {#s0010}
==========

2.1. Study design and database {#s0015}
------------------------------

This retrospective cohort study was conducted using a large-scale, anonymized database that combined medical claims data and health checkup data. Medical claims data from September 1, 2013 to August 31, 2014 were obtained from the Tokyo Extended Association of Medical Care for Latter-Stage Older People, which manages the medical insurance program for older adults residing in Tokyo, Japan. Japanese citizens are required to enroll in this insurance program on their 75th birthday. Data were acquired from 1,311,116 individuals (representing 97.1% of a total of 1,350,964 insured persons) for whom medical claims were generated during the study period. The data included patient-level sociodemographic characteristics, treatments, medical facilities used, prescribed drugs, and diagnoses made during clinical encounters.

We were provided health checkup data for the 2013 fiscal year (April 1, 2013 to March 31, 2014) from 52 of the 62 municipalities in Tokyo. These data included measurements for systolic BP (SBP), diastolic BP (DBP), HbA1c, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Using individual identification numbers generated for this study, we linked each individual's medical claims data with his/her corresponding health checkup data.

2.2. Patient selection {#s0020}
----------------------

[Fig. 1](#f0005){ref-type="fig"} shows the patient selection flow chart for Analyses I and II. From 1,218,235 insurance enrollees who had received outpatient care at a hospital or other medical institution between September 2013 and March 2014, we excluded 6709 patients aged \<75 years and 125,485 patients who were residing in the 10 municipalities that did not provide health checkup data. We analyzed health checkups that occurred between September 28, 2013 and March 31, 2014. Health checkups are performed once every fiscal year within each municipality at a medical facility for insured patients who reside within that municipality. In this study, we examined the use of pharmacological treatments in each patient during a 28-day period before his/her checkup (if the patient underwent a checkup in Analysis I). As we did not have access to medical claims data before September 1, 2013, we were only able to identify the pharmacological treatments of those who had undergone health checkups on September 28, 2013 or later. Therefore, a total of 265,266 patients who had undergone health checkups before September 28, 2013 were excluded from analysis. Furthermore, 560 patients who were hospitalized between September 2013 and March 2014 were also excluded from analysis because they were less likely to participate in health checkups than non-hospitalized patients. Analysis I was conducted using 820,215 patients.Fig. 1Flow chart of patient selection. ^a^Due to overlaps in pharmacological treatments, the total number of patients receiving each treatment in Analysis II does not add up to 259,498.

From the 274,210 patients who had undergone health checkups ([Fig. 1](#f0005){ref-type="fig"}), 14,712 patients with non-standard test values (i.e., outlier data) were excluded from analysis. The standard test values were obtained from the health checkup guidelines issued by Japan's Ministry of Health, Labour and Welfare ([@b0055]). Analysis II included 87,306, 24,541, and 70,206 patients who received pharmacological treatments for hypertension, diabetes, and dyslipidemia, respectively.

2.3. Definitions of pharmacological treatments for hypertension, diabetes, and dyslipidemia {#s0025}
-------------------------------------------------------------------------------------------

The definitions of pharmacological treatments for the target diseases in Analyses I and II are presented in [Fig. 2](#f0010){ref-type="fig"}. In Analysis I, a pharmacological treatment referred to any relevant therapeutic agent prescribed during the 28-day period from September 1 to 28, 2013. In Analysis II, a pharmacological treatment referred to any relevant therapeutic agent prescribed within the 28-day period immediately before each patient's health checkup. Accordingly, the pharmacological treatment statuses referred to prescriptions of any relevant therapeutic agent before a health checkup. These agents included antihypertensive agents for hypertension, antidiabetic agents and insulin preparations for diabetes, and hypolipidemic agents for dyslipidemia.Fig. 2Definitions of pharmacological treatments for hypertension, diabetes, and dyslipidemia in Analyses Ⅰ and Ⅱ.

2.4. Categories of disease control for hypertension, diabetes, and dyslipidemia {#s0030}
-------------------------------------------------------------------------------

For the treatment of hypertension, BP was classified as being under (a) intensive control (SBP \< 110 mmHg or DBP \< 60 mmHg), (b) moderate control (SBP 110--149 mmHg and DBP 60--89 mmHg), or (c) limited control (SBP ≥ 150 mmHg or DBP ≥ 90 mmHg) ([@b0065], [@b0035], [@b0020], [@b0095]).

For the treatment of diabetes, HbA1c levels (as defined by the National Glycohemoglobin Standardization Program) were classified as being under (a) intensive control (HbA1c \< 6.0%), (b) moderate control (HbA1c 6.0--6.9%), or (c) limited control (HbA1c ≥ 7.0%) ([@b0090], [@b0025], [@b0065], [@b0115], [@b0130], [@b0100]).

For the treatment of dyslipidemia, lipid levels were classified as being under (a) intensive control (LDL-C \< 100 mg/dl), (b) moderate control (LDL-C 100--139 mg/dl), or (c) limited control (LDL-C ≥ 140 mg/dl) ([@b0065], [@b0005]).

2.5. Other variables {#s0035}
--------------------

For Analysis I, we included the following covariates: sex, age, insurance copayment rate, home medical care use, number of outpatient facilities visited, and comorbidities. These were selected as potential factors of health checkup participation that are available in medical claims data and previously used in similar adjustment models ([@b0065], [@b0115], [@b0045], [@b0135]). For Analysis II, we included the following covariates: sex, age, insurance copayment rate, home medical care use, number of outpatient facilities visited, comorbidities, and pharmacological treatment. These were selected as potential factors of disease control for hypertension, diabetes, and dyslipidemia based on clinical guidelines and previous studies ([@b0025], [@b0035], [@b0045], [@b0065], [@b0090], [@b0095], [@b0115]). We had also included the pharmacological treatments for hypertension, diabetes, and dyslipidemia. For example, we included the pharmacological treatments for diabetes and dyslipidemia for patients receiving pharmacological treatment for hypertension. In Japan's health insurance system for older adults, the copayment rate is set at either 10% or 30%, depending on income. The higher rate is applicable to individuals who have a taxable income comparable to that of the working generation (≥¥1,450,000 per year, or approximately \$14,078). Following previously described methods, chronic diseases (dementia, osteoarthritis and spine disorders, cerebrovascular diseases, and coronary heart diseases) were identified based on International Classification of Diseases, Tenth Revision codes and records of the administration of drug classes that are specifically prescribed to treat these diseases in Japan ([@b0060]).

2.6. Statistical analysis {#s0040}
-------------------------

In Analysis I, the chi-squared test was used to compare characteristics between health checkup participants and non-participants. A binary logistic regression analysis was performed to examine the associations between pharmacological treatment statuses and health checkup participation. In the regression analysis, the dependent variable was health checkup participation or non-participation, and the independent variable of interest was pharmacological treatment for the target diseases. All other variables were treated as covariates.

In Analysis II, the chi-squared test was used to compare disease control categories (intensive, moderate, or limited) among patients receiving pharmacological treatments for each specific disease. Multinomial logistic regression analyses were then performed to examine the factors associated with the management of each disease using the disease control categories as the dependent variables (reference: moderate control). We calculated the adjusted odds ratios and 95% confidence intervals for each variable.

*P* values (2-sided) below 0.05 were considered statistically significant. All analyses were conducted using SPSS version 23.0 (IBM Corp, Armonk, NY, USA).

2.7. Ethical considerations {#s0045}
---------------------------

The study protocol was approved by the Ethics Committee of the Tokyo Metropolitan Institute of Gerontology. We performed all analyses in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the Japanese government.

3. Results {#s0050}
==========

A total of 820,215 patients were included in Analysis I ([Table 1](#t0005){ref-type="table"}). Women accounted for 62.3% of all patients, and the 75--79 year age group was the largest (accounting for 40.9% of all patients). Approximately 85.2% of patients used the 10% copayment rate, 7.7% of patients used home medical care, and 38.9% visited 2--3 outpatient facilities. Approximately 40% of patients were receiving pharmacological treatments for hypertension, diabetes, and/or dyslipidemia. The pharmacological treatment rates were 27.4% for hypertension, 9.3% for diabetes, and 19.7% for dyslipidemia.Table 1Patient characteristics (n = 820,215).Characteristicsn%SexMen309,23037.7Women510,98562.3Age (years)75--79335,07840.980--84244,56729.885--89150,80418.4≥9089,76610.9Copayment rate10%699,16885.230%121,04714.8Home medical care useNo756,67792.3Yes63,5387.7Number of outpatient facilities visited149,4886.02--3318,77438.94--5242,93129.6≥6209,02225.5Chronic diseasesDementiaNo750,06591.4Yes70,1508.6Osteoarthritis/Spine disordersNo637,71277.7Yes182,50322.3Cerebrovascular diseasesNo641,81278.2Yes178,40321.8Coronary heart diseasesNo614,56574.9Yes205,65025.1Pharmacological treatment for hypertension, diabetes, and/or dyslipidemiaNo494,80260.3Yes325,41339.7

3.1. Associations of pharmacological treatments and other variables with health checkup participation {#s0055}
-----------------------------------------------------------------------------------------------------

Approximately 38% of patients receiving pharmacological treatment for hypertension, diabetes, and/or dyslipidemia underwent health checkups, and approximately 31% of patients not receiving these pharmacological treatments underwent health checkups ([Table 2](#t0010){ref-type="table"}). The results of the binary logistic regression analysis demonstrated that patients who were receiving pharmacological treatments were more likely to participate in health checkups than those not receiving pharmacological treatments (adjusted odds ratio: 1.374, 95% confidence interval: 1.360--1.388, *P* \< 0.001). Furthermore, older adults who visited a higher number of outpatient facilities were more likely to undergo health checkups than those who visited only one facility.Table 2Associations of pharmacological treatments with health checkup participation (n = 820,215).Health checkup\
participants\
n = 274,210Health checkup\
non-participants\
n = 546,005Logistic regression analysis that adjusted for all covariatesHealth checkup participation\
Reference: Health checkup non-participationn%n%*P* value[a](#tblfn1){ref-type="table-fn"}AOR95% CI*P* valuePharmacological treatment for hypertension, diabetes, and/or dyslipidemiaNo150,75130.5344,05169.5\<0.0011.000Yes123,45937.9201,95462.11.374(1.360--1.388)\<0.001SexMen99,99332.3209,23767.7\<0.0011.000Women174,21734.1336,76865.91.089(1.078--1.100)\<0.001Age (years)75--79116,63634.8218,44265.2\<0.0011.00080--8494,00238.4150,56561.61.208(1.194--1.222)\<0.00185--8945,89830.4104,90669.60.958(0.944--0.971)\<0.001≥9017,67419.772,09280.30.653(0.640--0.665)\<0.001Copayment rate10%234,53933.5464,62966.5\<0.0011.00030%39,67132.881,37667.20.946(0.933--0.959)\<0.001Home medical care useNo268,15935.4488,51864.6\<0.0011.000Yes6,0519.557,48790.50.239(0.232--0.246)\<0.001Number of outpatient facilities visited111,33822.938,15077.1\<0.0011.0002--383,44126.2235,33373.81.313(1.283--1.344)\<0.0014--587,26235.9155,66964.12.018(1.971--2.066)\<0.001≥692,16944.1116,85355.92.756(2.691--2.823)\<0.001Chronic diseasesDementiaNo258,40234.5491,66365.5\<0.0011.000Yes15,80822.554,34277.50.694(0.681--0.708)\<0.001Osteoarthritis/Spine disordersNo203,07031.8434,64268.2\<0.0011.000Yes71,14039.0111,36361.01.072(1.059--1.085)\<0.001Cerebrovascular diseasesNo223,87734.9417,93565.1\<0.0011.000Yes50,33328.2128,07071.80.757(0.747--0.766)\<0.001Coronary heart diseasesNo212,16734.5402,39865.5\<0.0011.000Yes62,04330.2143,60769.80.746(0.737--0.754)\<0.001[^1][^2]

3.2. Distribution of BP, HbA1c, and lipid levels in annual health checkup participants {#s0060}
--------------------------------------------------------------------------------------

[Fig. 3](#f0015){ref-type="fig"} shows the distribution of BP, HbA1c, and lipid levels among health checkup participants. Among patients receiving pharmacological treatment for hypertension, 17% had SBP ≥150 mmHg (limited control) and 3% had SBP \<110 mmHg (intensive control). Among patients receiving pharmacological treatment for diabetes, 30% had HbA1c levels ≥7.0% (limited control) and 45% had HbA1c levels \<6.5% (intensive control). Among patients receiving pharmacological treatment for dyslipidemia, 10% had LDL-C levels ≥140 mg/dl (limited control) and 40% had LDL-C levels \<100 mg/dl (intensive control).Fig. 3Distribution of blood pressure, HbA1c level, and lipid levels among health checkup participants.

3.3. Factors associated with BP in patients receiving pharmacological treatment for hypertension {#s0065}
------------------------------------------------------------------------------------------------

Patients with intensive control of BP were more likely to be men; ≥90 years old; use home medical care; visited more than one outpatient facility for treatment; and have dementia, cerebrovascular diseases, and coronary heart diseases than patients with moderate control ([Table 3](#t0015){ref-type="table"}). In contrast, patients with limited control were more likely to be aged ≥80 years, less likely to have dementia and coronary heart diseases, and less likely to have visited more than one outpatient facility than patients with moderate control.Table 3Factors associated with blood pressure among patients receiving pharmacological treatment for hypertension (n = 87,306).(a) Intensive control\
SBP \< 110 mmHg or\
DBP \< 60 mmHg\
n = 2728(b) Moderate control\
SBP: 110--149 mmHg and\
DBP: 60--89 mmHg\
n = 17,665(c) Limited control\
SBP ≥ 150 mmHg or\
DBP ≥ 90 mmHg\
n = 66,913Multinomial logistic regression analysis that adjusted for all covariates\
Reference: (b) Moderate control(a) Intensive control(c) Limited controln%n%n%P value[a](#tblfn2){ref-type="table-fn"}AOR95% CIAOR95% CISexMen1,0833.46,35220.024,29276.60.00111Women1,6453.011,31320.442,62176.70.866(0.799--0.939)1.024(0.988--1.062)Age (years)75--799692.96,47719.425,95977.7\<0.001180--849483.06,27520.123,98076.91.012(0.923--1.109)1.065(1.025--1.108)85--895503.33,49421.212,40575.41.068(0.958--1.192)1.151(1.098--1.206)≥902614.21,41922.74,56973.11.279(1.104--1.481)1.248(1.167--1.335)Copayment rate10%2,3483.115,35920.357,80976.60.131130%3803.22,30619.69,10477.21.006(0.900--1.125)0.963(0.916--1.012)Home medical care useNo2,5833.017,31620.365,52276.7\<0.00111Yes1457.734918.51,39173.82.144(1.781--2.581)0.886(0.784--1.000)Number of outpatient facilities visited1502.062224.31,88573.7\<0.001112--37713.05,59221.919,13075.01.402(1.048--1.875)0.896(0.814--0.986)4--58793.15,82620.421,79276.51.438(1.076--1.922)0.822(0.747--0.905)≥61,0283.35,62518.324,10678.41.541(1.153--2.060)0.721(0.655--0.794)Chronic diseasesDementiaNo2,4613.016,73020.462,96876.6\<0.00111Yes2675.293518.23,94576.61.458(1.272--1.670)0.863(0.801--0.930)Osteoarthritis/Spine disordersNo2,0083.212,72520.447,61776.40.00311Yes7202.94,94019.819,29677.30.869(0.794--0.951)1.011(0.972--1.050)Cerebrovascular diseasesNo1,9442.913,84520.551,75276.6\<0.00111Yes7844.03,82019.315,16176.71.247(1.143--1.360)0.969(0.930--1.009)Coronary heart diseasesNo1,7042.812,76320.747,08576.5\<0.00111Yes1,0244.04,90219.019,82877.01.368(1.262--1.483)0.927(0.893--0.963)Pharmacological treatmentFor diabetesNo2,3353.114,99020.157,16676.70.14411Yes3933.12,67520.99,74776.10.960(0.860--1.072)1.078(1.029--1.130)For dyslipidemiaNo1,6513.111,13020.940,37376.0\<0.00111Yes1,0773.26,53519.126,54077.71.007(0.929--1.091)0.9(0.869--0.932)[^3][^4]

3.4. Factors associated with HbA1c levels in patients receiving pharmacological treatment for diabetes {#s0070}
------------------------------------------------------------------------------------------------------

When compared with patients with moderate control of HbA1c levels, those with intensive control were more likely to be ≥80 years old, use home medical care, and have osteoarthritis/spine disorders ([Table 4](#t0020){ref-type="table"}). In contrast, patients with limited control were more likely to have dementia, but less likely to have osteoarthritis/spine disorders or to be receiving pharmacological treatment for hypertension.Table 4Factors associated with HbA1c levels among patients receiving pharmacological treatment for diabetes (n = 24,541).(a) Intensive control\
HbA1c \< 6.0%n = 5102(b) Moderate control\
HbA1c: 6.0--6.9%\
n = 15,998(c) Limited control\
HbA1c ≥ 7.0%n = 7234Multinomial logistic regression analysis that adjusted for all covariates\
Reference: (b) Moderate control(a) Intensive control(c) Limited controln%n%n%*P* value[a](#tblfn3){ref-type="table-fn"}AOR95% CIAOR95% CISexMen2,18019.75,53350.03,35130.3\<0.00111Women2,92221.76,67249.53,88328.81.068(0.997--1.145)0.996(0.937--1.058)Age (years)75--791,88818.15,35951.43,17630.5\<0.0011180--841,95421.94,35648.92,60129.21.237(1.147--1.334)1.008(0.944--1.077)85--8993223.21,94348.51,13428.31.276(1.159--1.405)0.974(0.893--1.063)≥9032827.454745.732327.01.546(1.330--1.798)0.958(0.826--1.110)Copayment rate10%4,43521.010,46849.66,18429.30.061130%66719.31,73750.31,05030.40.938(0.850--1.034)1.012(0.931--1.101)Home medical care useNo4,94620.711,95249.97,05029.40.03511Yes15626.325342.718431.01.243(1.008--1.533)1.192(0.979--1.452)Number of outpatient facilities visited112819.032147.722433.3\<0.001112--31,32819.43,45150.32,08230.30.922(0.743--1.144)0.866(0.723--1.036)4--51,68420.54,02549.02,51030.50.957(0.772--1.186)0.909(0.760--1.086)≥61,96222.34,40850.22,41827.50.943(0.761--1.170)0.819(0.684--0.980)Chronic diseasesDementiaNo4,74720.711,49050.06,74529.30.00611Yes35522.871545.948931.41.116(0.974--1.279)1.132(1.002--1.278)Osteoarthritis/Spine disordersNo3,16618.18,81750.55,48131.4\<0.00111Yes1,93627.43,38847.91,75324.81.575(1.464--1.694)0.856(0.798--0.918)Cerebrovascular diseasesNo3,85320.49,45750.15,57829.50.01911Yes1,24922.12,74848.61,65629.31.081(0.999--1.169)1.03(0.959--1.105)Coronary heart diseasesNo3,58820.78,57149.65,13529.70.51611Yes1,51420.93,63450.12,09929.00.984(0.915--1.059)0.992(0.929--1.058)Pharmacological treatmentFor hypertensionNo2,44920.95,65748.23,62030.9\<0.00111Yes2,65320.76,54851.13,61428.20.946(0.885--1.011)0.871(0.821--0.923)For dyslipidemiaNo3,08823.26,32847.63,87529.2\<0.00111Yes2,01417.95,87752.23,35929.90.703(0.657--0.753)0.949(0.894--1.008)[^5][^6]

3.5. Factors associated with lipid levels in patients receiving pharmacological treatment for dyslipidemia {#s0075}
----------------------------------------------------------------------------------------------------------

When compared with patients with moderate control of lipid levels, those with intensive control were more likely to be men; ≥80 years old; use home medical care; and have dementia, osteoarthritis/spine disorders, cerebrovascular diseases, and coronary heart diseases ([Table 5](#t0025){ref-type="table"}). These patients were also more likely to be receiving pharmacological treatment for hypertension and diabetes. In contrast, patients with limited control were more likely to be women and have dementia than patients with moderate control. Furthermore, patients with limited control were less likely to have cerebrovascular and coronary heart diseases or to be receiving pharmacological treatment for hypertension and diabetes.Table 5Factors associated with lipid levels among patients receiving pharmacological treatment for dyslipidemia (n = 70,206).(a) Intensive control\
LDL-C \< 100 mg/dl\
n = 27,801(b) Moderate control\
LDL-C: 100--139 mg/dl\
n = 34,970(c) Limited control\
LDL-C ≥ 140 mg/dl\
n = 7,435Multinomial logistic regression analysis that adjusted for all covariates\
Reference: (b) Moderate control(a) Intensive control(c) Limited controln%n%n%*P* value[a](#tblfn4){ref-type="table-fn"}AOR95% CIAOR95% CISexMen9,12047.48,50544.21,6288.5\<0.00111Women18,68136.726,46551.95,80711.40.688(0.663--0.713)1.123(1.056--1.194)Age (years)75--7911,04536.615,62651.83,50211.6\<0.0011180--8410,22040.412,45949.32,59110.31.121(1.081--1.162)0.944(0.892--0.999)85--894,94243.65,35547.21,0439.21.234(1.177--1.293)0.886(0.820--0.957)≥901,59446.61,53044.72998.71.401(1.298--1.512)0.878(0.770--1.001)Copayment rate10%24,01039.630,21849.86,39910.60.7321130%3,79139.64,75249.61,03610.80.951(0.908--0.997)1.039(0.966--1.118)Home medical care useNo27,24339.434,52149.97,35010.6\<0.00111Yes55851.144941.1857.81.356(1.192--1.544)0.905(0.713--1.148)Number of outpatient facilities visited177338.899249.822811.40.001112--37,57838.59,87750.22,20811.20.933(0.844--1.031)0.994(0.854--1.156)4--59,23039.811,53749.82,41010.40.969(0.877--1.070)0.935(0.804--1.088)≥610,22040.312,56449.52,58910.20.968(0.876--1.070)0.934(0.802--1.087)Chronic diseasesDementiaNo26,12139.433,20450.07,02010.6\<0.00111Yes1,68043.51,76645.741510.71.085(1.010--1.165)1.17(1.045--1.310)Osteoarthritis/Spine disordersNo19,52439.324,77349.95,35810.80.00711Yes8,27740.310,19749.62,07710.11.054(1.016--1.093)0.957(0.903--1.014)Cerebrovascular diseasesNo21,03938.028,12250.96,14211.1\<0.00111Yes6,76245.46,84846.01,2938.71.187(1.142--1.235)0.902(0.844--0.964)Coronary heart diseasesNo18,06336.525,74852.05,73711.6\<0.00111Yes9,73847.19,22244.61,6988.21.369(1.322--1.418)0.873(0.822--0.927)Pharmacological treatmentFor hypertensionNo12,89535.818,75652.04,40312.2\<0.00111Yes14,90643.616,21447.53,0328.91.243(1.203--1.283)0.823(0.782--0.866)For diabetesNo22,43838.129,97450.86,54411.1\<0.00111Yes5,36347.74,99644.48917.91.34(1.284--1.399)0.845(0.782--0.912)[^7][^8]

4. Discussion {#s0080}
=============

This study integrated health checkup data and medical claims data from Tokyo residents aged ≥75 years to analyze the associations between pharmacological treatments for three major lifestyle diseases and health checkup participation, as well as to explore the factors associated with disease control. The results showed that older adults who were actively receiving pharmacological treatments for hypertension, diabetes, and dyslipidemia were more likely to participate in health checkups than those not being treated. In addition, patients undergoing intensive control in all three target diseases were more likely to be older and to be using home medical care than those undergoing moderate control.

Older adults who were already receiving pharmacological treatments for hypertension, diabetes, and/or dyslipidemia were more likely to participate in health checkups that those not receiving these treatments. Although the Organization for Economic Co-operation and Development has recommended reducing inefficiencies in the Japanese health checkup system ([@b0080]), our findings raise questions about the efficiency of having older adults participate in health checkups that are primarily designed to identify individuals at risk of developing these target diseases. The study also revealed that health checkup participants visited more outpatient facilities than non-participants. It has been reported that the greater the number of outpatient facilities visited, the higher the risk of drug-related adverse events ([@b0070]). It may be possible to modify the health checkup system for older adults so that it can ascertain the statuses of patients' pharmacological treatments and provide this information to their outpatient facilities in order to prevent such adverse events.

Analysis II found that among the older adults receiving pharmacological treatments for the target diseases, those aged ≥90 years and using home medical care were more likely to be undergoing intensive disease control. Cognitive and physical functional statuses decline with progressive aging ([@b0125]), and patients who use home medical care are presumed to have lower functionalities that render them unable to attend outpatient facilities. With consideration to functional decline in older persons, treatment guidelines for hypertension and diabetes recommend using less intensive clinical measures for this group than for younger patients ([@b0025], [@b0095]). Nevertheless, our results indicated that hypertension and diabetes were intensively controlled in older adults with declining cognitive and physical function, which is not concordant with treatment guidelines ([@b0025], [@b0095]). It has been pointed out that evaluating cognitive and physical functional statuses in an outpatient setting is difficult due to consultation time constraints ([@b0025]). The inability to accurately evaluate patients' functional statuses in an outpatient setting may have contributed to the intensive management of BP and HbA1c observed in our subjects. The current health checkup system could benefit from the inclusion of functional status evaluations for older adults, with results provided to outpatient medical facilities to make it easier for the attending physicians to manage treatments.

The use of insulin preparations and sulfonylurea drugs for diabetes is associated with an elevated risk of hypoglycemia. As a preventive measure, the recommended lower limit for HbA1c is set at 7.0% ([@b0025]). However, approximately 30% (7234/24,541) of the older adults receiving pharmacological treatment for diabetes in our study had their HbA1c managed to a level below 7.0%. Further studies are needed to ascertain the prevalence and appropriateness of insulin preparation and sulfonylurea drug use among older diabetic patients with aggressively controlled HbA1c values (\<7.0%) to examine hypoglycemia prevention strategies.

This study has several limitations. First, the determination of whether or not a patient was receiving pharmacological treatment was based on the number of prescription days within a 28-day period. Patients receiving treatments for more than 28 days were not regarded as receiving pharmacological treatment, which may have led to an underestimation of these patients. We conducted an additional sensitivity analysis using a 35-day period for pharmacological treatment to assess the effects of patients with longer-term prescriptions on our findings. The results for both analyses were similar to the study's main results, which indicated that the inclusion of patients with longer prescriptions would have little effect on our conclusions. Second, the health checkups were conducted at medical facilities, and the BP estimates may be susceptible to the "white coat" effect. As a result, the numbers of people with intensive and limited control of BP may have been underestimated and overestimated, respectively, in Analysis II. Third, the study included only older adults living in Tokyo. Approximately 52% of older adults in Tokyo participate in health checkups, which is substantially higher than the national average of 25% ([@b0110]). This may limit the generalizability of our findings. Fourth, education level was not included in the analysis as it was not available in the claims data or health checkup data. This increases the risk of residual confounding in our analysis. Because education level may be associated with lower pharmacological treatment ([@b0045]) and increased health checkup participation ([@b0135]), the positive associations between pharmacological treatments and health checkup participation may have been overestimated in Analysis I. However, the copayment rate has been reported to be associated with education level ([@b0105]), and the inclusion of the former in Analysis I may have allowed for some degree of adjustment for the latter. Finally, the subjects for Analysis II were all extracted from the health checkup participants in Analysis I. Users of home medical care are less likely to participate in health checkups, and residents of long-term care facilities were not included in this study. Therefore, the subjects in Analysis II may have been biased toward older adults with relatively good cognitive and physical functional statuses. Nevertheless, the lack of an ideal comprehensive data source means that our approach of linking medical claims data and checkup data may represent the best available option for monitoring the pharmaceutical management of hypertension, diabetes, and dyslipidemia.

5. Conclusion {#s0085}
=============

Our study demonstrated that older adults receiving pharmacological treatments for hypertension, diabetes, and dyslipidemia were more likely to participate in health checkups. This suggests that it may be inefficient to conduct health checkups simply aimed at identifying older adults at risk of developing these diseases. It may be beneficial to consider the modification of these checkups to provide active feedback to each patient's outpatient clinic and facilitate disease control monitoring. In addition, hypertension and diabetes were found to be more intensively controlled in older adults despite reduced cognitive and physical function, which contravenes treatment guidelines. The linkage of claims data and health checkup data may enable the monitoring of chronic disease management in older adults, and our findings may contribute to the evaluation and improvement of the health checkup system.
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[^1]: Abbreviation: AOR, adjusted odds ratio; CI: confidence interval.

[^2]: *P* value: χ^2^ test.

[^3]: Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure.

[^4]: *P* value: χ^2^ test.

[^5]: Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; HbA1c, hemoglobin A1c.

[^6]: *P* value: χ^2^ test

[^7]: Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol.

[^8]: *P* value: χ^2^ test.
